Cefdinir clinical studies: Difference between revisions
Created page with "__NOTOC__ {{Cefdinir}} {{CMG}} '''Community-Acquired Bacterial Pneumonia''': In a controlled, double-blind study in adults and adolescents conducted in the U.S., cefdinir BI..." |
No edit summary |
||
| Line 9: | Line 9: | ||
{| | {| | ||
|- | |- | ||
|[[File:Cefdinir 9.jpg|thumb| | |[[File:Cefdinir 9.jpg|thumb|800px|left]] | ||
|- | |- | ||
|} | |} | ||
| Line 18: | Line 18: | ||
{| | {| | ||
|- | |- | ||
|[[File:Cefdinir 10.jpg|thumb| | |[[File:Cefdinir 10.jpg|thumb|800px|left]] | ||
|- | |- | ||
|} | |} | ||
| Line 28: | Line 28: | ||
{| | {| | ||
|- | |- | ||
|[[File:Cefdinir 11.jpg|thumb| | |[[File:Cefdinir 11.jpg|thumb|800px|left]] | ||
|- | |- | ||
|} | |} | ||
| Line 37: | Line 37: | ||
{| | {| | ||
|- | |- | ||
|[[File:Cefdinir 12.jpg|thumb| | |[[File:Cefdinir 12.jpg|thumb|800px|left]] | ||
|- | |- | ||
|} | |}<ref>{{Cite web | last = |first = |title = http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/50739S2LBL.pdf |url =http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/50739S2LBL.pdf |publisher = |date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
Revision as of 20:26, 23 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Community-Acquired Bacterial Pneumonia:
In a controlled, double-blind study in adults and adolescents conducted in the U.S., cefdinir BID was compared with cefaclor 500 mg TID. Using strict evaluability and microbiologic/clinical response criteria 6 to 14 days posttherapy, the following clinical cure rates, presumptive microbiologic eradication rates, and statistical outcomes were obtained:
 |
In a second controlled, investigator-blind study in adults and adolescents conducted primarily in Europe, cefdinir BID was compared with amoxicillin/clavulanate 500/125 mg TID. Using strict evaluability and clinical response criteria 6 to 14 days posttherapy, the following clinical cure rates, presumptive microbiologic eradication rates, and statistical outcomes were obtained:
 |
Streptococcal Pharyngitis/Tonsillitis:
In four controlled studies conducted in the U.S., cefdinir was compared with 10 days of penicillin in adult, adolescent, and pediatric patients. Two studies (one in adults and adolescents, the other in pediatric patients) compared 10 days of cefdinir QD or BID to penicillin 250 mg or 10 mg/kg QID. Using strict evaluability and microbiologic/clinical response criteria 5 to 10 days posttherapy, the following clinical cure rates, microbiologic eradication rates, and statistical outcomes were obtained:
 |
Two studies (one in adults and adolescents, the other in pediatric patients) compared 5 days of cefdinir BID to 10 days of penicillin 250 mg or 10 mg/kg QID. Using strict evaluability and microbiologic/ clinical response criteria 4 to 10 days posttherapy, the following clinical cure rates, microbiologic eradication rates, and statistical outcomes were obtained:
 |
References
- ↑ "http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/50739S2LBL.pdf" (PDF). External link in
|title=(help)
Adapted from the FDA Package Insert.